Suppr超能文献

SLC22A12(URAT1)基因杂合突变导致肾脏低尿酸血症的肾移植:病例报告。

Transplantation of a kidney with a heterozygous mutation in the SLC22A12 (URAT1) gene causing renal hypouricemia: a case report.

机构信息

Department of Nephrology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

出版信息

BMC Nephrol. 2020 Jul 16;21(1):282. doi: 10.1186/s12882-020-01940-4.

Abstract

BACKGROUND

Renal hypouricemia (RHUC) is a genetic disorder caused by mutations in the SLC22A12 gene, which encodes the major uric acid (UA) transporter, URAT1. The clinical course of related, living donor-derived RHUC in patients undergoing kidney transplantation is poorly understood. Here, we report a case of kidney transplantation from a living relative who had an SLC22A12 mutation. After the transplantation, the recipient's fractional excretion of UA (FEUA) decreased, and chimeric tubular epithelium was observed.

CASE PRESENTATION

A 40-year-old man underwent kidney transplantation. His sister was the kidney donor. Three weeks after the transplantation, he had low serum-UA, 148.7 μmol/L, and elevated FEUA, 20.8% (normal: < 10%). The patient's sister had low serum-UA (101.1 μmol/L) and high FEUA (15.8%) before transplant. Suspecting RHUC, we performed next-generation sequencing on a gene panel containing RHUC-associated genes. A heterozygous missense mutation in the SLC22A12 gene was detected in the donor, but not in the recipient. The recipient's serum-UA level increased from 148.7 μmol/L to 231.9 μmol/L 3 months after transplantation and was 226.0 μmol/L 1 year after transplantation. His FEUA decreased from 20.8 to 11.7% 3 months after transplantation and was 12.4% 1 year after transplantation. Fluorescence in situ hybridization of allograft biopsies performed 3 months and 1 year after transplantation showed the presence of Y chromosomes in the tubular epithelial cells, suggesting the recipient's elevated serum-UA levels were owing to a chimeric tubular epithelium.

CONCLUSIONS

We reported on a kidney transplant recipient that developed RHUC owing to his donor possessing a heterozygous mutation in the SLC22A12 (URAT1) gene. Despite this mutation, the clinical course was not problematic. Thus, the presence of donor-recipient chimerism in the tubular epithelium might positively affect the clinical course, at least in the short-term.

摘要

背景

肾性低尿酸血症(RHUC)是一种由 SLC22A12 基因突变引起的遗传疾病,该基因编码主要的尿酸(UA)转运体 URAT1。在接受肾移植的患者中,与活体供体来源的 RHUC 相关的临床病程尚不清楚。在这里,我们报告了一例由携带 SLC22A12 突变的活体亲属进行的肾移植病例。移植后,受者的 UA 分数排泄(FEUA)下降,并观察到嵌合管状上皮。

病例介绍

一名 40 岁男性接受了肾移植。他的妹妹是肾脏供体。移植后 3 周,他的血清-UA 水平较低,为 148.7μmol/L,FEUA 升高,为 20.8%(正常:<10%)。供者在移植前血清-UA 水平较低(101.1μmol/L),FEUA 水平较高(15.8%)。怀疑为 RHUC,我们对包含 RHUC 相关基因的基因panel 进行了下一代测序。在供体中发现 SLC22A12 基因的杂合错义突变,但在受者中未发现。受者的血清-UA 水平从 148.7μmol/L 增加到移植后 3 个月的 231.9μmol/L,1 年后增加到 226.0μmol/L。他的 FEUA 从移植后 3 个月的 20.8%下降到 11.7%,1 年后下降到 12.4%。移植后 3 个月和 1 年后的移植肾活检的荧光原位杂交显示肾小管上皮细胞中存在 Y 染色体,提示受者血清-UA 水平升高是由于嵌合管状上皮所致。

结论

我们报告了一例肾移植受者,由于其供体携带 SLC22A12(URAT1)基因的杂合突变而发生 RHUC。尽管存在这种突变,但临床病程并无问题。因此,管状上皮中供体-受者嵌合体的存在可能会对至少短期的临床病程产生积极影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41d9/7364597/108ce7b7def0/12882_2020_1940_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验